What is the price target for VINC stock?
7 analysts have analysed VINC and the average price target is 204 USD. This implies a price increase of 203900% is expected in the next year compared to the current price of 0.1.
VINCERX PHARMA INC (VINC) Forecast, Price Target & Analyst Ratings
NASDAQ:VINC • US92731L3042
Current stock price
0.1 USD
-0.03 (-24.98%)
At close:
0.0639 USD
-0.04 (-36.1%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VINCERX PHARMA INC (VINC).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Estimate
- -$0.12
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$204.00
Upside
+ 203,900.00%
From current price of $0.10 to mean target of $204.00, Based on 7 analyst forecasts
Low
$202.00
Median
$204.00
High
$210.00
Price Target Revisions
1 Month
0.00%
3 Months
3,233.33%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for VINC. The average price target is 204 USD. This implies a price increase of 203900% is expected in the next year compared to the current price of 0.1.
The average price target has been revised upward by 3233.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
VINC was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VINC.
In the previous month the buy percentage consensus was at a similar level.
VINC was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-08 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-04-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-04-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2022-11-17 | Chardan Capital | Maintains | Buy |
| 2022-08-12 | SVB Leerink | Maintains | Outperform |
| 2022-06-08 | Cantor Fitzgerald | Maintains | Overweight |
| 2022-06-07 | Chardan Capital | Maintains | Buy |
| 2022-06-07 | B. Riley Securities | Maintains | Buy |
| 2022-06-07 | SVB Leerink | Maintains | Outperform |
| 2022-05-13 | Chardan Capital | Maintains | Buy |
| 2022-05-13 | SVB Leerink | Maintains | Outperform |
| 2022-01-14 | HC Wainwright & Co. | Initiate | Buy |
| 2021-12-23 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-11-01 | SVB Leerink | Initiate | Outperform |
| 2021-09-13 | Laidlaw & Co. | Initiate | Buy |
| 2021-08-25 | B. Riley Securities | Initiate | Buy |
| 2021-08-13 | Chardan Capital | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Estimate
- -$0.12
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 98.94%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
VINC is expected to report earnings on 5/12/2025. The consensus EPS estimate for the next earnings is -0.12 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 3,331.82% | N/A 227.15% | N/A 168.58% | N/A 71.96% | N/A 45.87% | |||||||
| EBITDA YoY % growth | N/A | N/A | -62.631M | -68.668M -9.64% | -42.557M 38.02% | -31.411M 26.19% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.4K | -173K -12,257.14% | -62.656M -36,117.34% | -68.722M -9.68% | -42.609M 38.00% | -31.463M 26.16% | N/A 10.44% | N/A -41.18% | N/A -64.10% | N/A 6.25% | N/A 45.00% | N/A 106.06% | N/A 2,000.00% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -2.28 -24.18% | -3.12 -36.84% | -1.89 39.42% | -20.20 -968.78% | N/A 39.41% | N/A 95.25% | N/A -49.12% | N/A 12.94% | N/A 50.00% | N/A 113.51% | N/A 900.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 98.94% | -0.12 87.76% | -0.12 96.40% | -0.11 97.33% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.12M 18.16% | -6.12M 16.92% | -6.12M 21.47% | -6.12M 30.66% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.08%
EPS Next 5 Year
14.65%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VINCERX PHARMA INC / VINC Forecast FAQ
What is the next earnings date for VINC stock?
VINCERX PHARMA INC (VINC) will report earnings on 2025-05-12.
Can you provide the consensus estimates for VINCERX PHARMA INC next earnings?
The consensus EPS estimate for the next earnings of VINCERX PHARMA INC (VINC) is -0.12 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed VINCERX PHARMA INC (VINC)?
The number of analysts covering VINCERX PHARMA INC (VINC) is 7.